

Investor Newsletter


Issue **09** 2019



Endovastec™ Gains CE Mark for **Minos™** Ultra-Low Profile Abdominal Aortic Aneurysm Stent Graft System

Shanghai MicroPort Endovascular MedTech Co., Ltd. (“Endovastec™”) gained CE Mark for its Minos™ Ultra-Low Profile Abdominal Aortic Aneurysm Stent Graft System (“Minos™ Stent Graft”) on September 12, which is the first for the company’s aortic stent graft devices. The European approval came after Endovastec™ successfully applied for the approval for the device from National Medical Products Administration of China (NMPA) in March. Minos™ stent Graft has become the third device produced by Endovastec™ with CE Mark, following Hercules™ Balloon Dilation Catheter and Reewarm™ Peripheral Balloon Dilation Catheter.

Endovastec™ President Zhenghua Miao said, “Endovastec™ will continue to remain committed to the promotion of more high-quality and innovative high-end medical devices in the global market to provide patients with the therapeutic solutions of more comprehensiveness.”



MicroPort® CRM Japan Starts Direct Sales Operations in Japan and Launches the New ENO™ Pacemaker Family

MicroPort® CRM Japan Co. Ltd. is pleased to announce it has started direct sales operations since September 2019, with the first four implants of the KORA™ pacemakers that have been performed in several regions in Japan.

MicroPort® CRM Japan is a subsidiary of MicroPort® CRM and established in August 2018 with the objective to take over the direct distribution of CRM products in Japan from September 1, 2019.

MicroPort® CRM Japan will start introducing ENO™ in Japan, a new range of pacemakers with a volume of only 8cc. ENO™ pacemakers feature AutoMRI™ technology, allowing patients implanted with compatible leads to undergo MRI (Magnetic Resonance Imaging) scans in either 1.5 Tesla or 3 Tesla machines. AutoMRI™ automatically switches in and out of MRI mode upon detection of the MR field, ensuring appropriate pacemaker operation during the scan and allowing patients to benefit from optimal pacing settings right up to and just after the scan.





MicroPort® CRM Announces First Implant in Japan of the New Eno™ Pacemaker Family, World's Smallest 1.5T & 3T MRI Conditional Pacemakers

MicroPort® CRM, is pleased to announce the first implant of its new Eno™ pacemaker family in Japan.

Eno™ pacemaker's technology allows patients implanted with compatible leads to undergo MRI (Magnetic Resonance Imaging) scans in either 1.5 Tesla or 3 Tesla machines.

The new pacemaker family also features:

- AutoMRI™: an automatic mode adaptation upon detection of the MRI field that protects patients who enjoy their optimal pacing settings right up to and right after the scan.

- Phi Intelligence™: a permanent adaptive pacing strategy that responds to all levels of patient activity, day and night, evolving and learning with the patient's conditions in order to mimic the natural way the heart works, minimizing artificial intervention.
- AF Risk Management™: a unique combination of features that helps physicians to accurately detect Atrial Fibrillation (AF), minimize ventricular pacing and screen for sleep apnea so as to protect patients from developing AF.
- Preset Fit™: a set of capabilities including precision programming calibrated through clinical experience and designed to facilitate the implant procedure and device follow up.

*Transvenous cardiac pacing systems

Inauguration of International Shared Services Center in **Costa Rica**

MicroPort® Orthopedics, which is a subsidiary of MicroPort Scientific Corporation (“MicroPort®”), announces the inauguration of its International Shared Services Center in Costa Rica. The Costa Rica Site provides support for the global markets of MicroPort® Orthopedics. The main responsibility for this site would be applying remote image processing to construct three-dimensional models of joints for patients across the world, and then designing a personalized osteotomy positioning tool for the patient, thereby improving the accuracy and success rate of total knee replacement surgery.



The Costa Rica Site covers the following functions: Accounting and Finance, Purchasing, Customer Service, Human Resources, IT, Compliance and Quality. The R&D team will support product development and product updates. Currently, MicroPort® Orthopedics has 50 employees in Costa Rica and expects to increase to 70 by the end of 2020. The inauguration of the new Shared Services Center will continue to support global markets.

Minister of Foreign Trade of Costa Rica Ms. Dyalá Jiménez said, “We are proud of the expansion of MicroPort® Orthopedics in Costa Rica, which shown investors’ confidence in our strength, such as human capital. We hereby express our congratulation to MicroPort® Orthopedics.”



MicroPort® Exhibits Integrated Solutions for Interventional Cardiology at TCT 2019



On September 25-29, MicroPort® displayed integrated solutions for interventional cardiology at the 31th edition of Transcatheter Cardiovascular Therapeutics 2019 (TCT 2019) which was held in San Francisco, US, and brought together about 10,000 interventional cardiologists from over 100 countries and regions.

At TCT 2019, MicroPort® also exhibited the integrated solutions for interventional cardiology, comprising the innovative devices of Firehawk® Rapamycin Target Eluting Coronary Stent System, Firefighter® PTCA balloon dilation catheter, Firehawk® Liberty Rapamycin Target Eluting Coronary Stent System and Firefighter® NC PTCA balloon dilation catheter, which drew a great number of attendees at the congress to the booth of MicroPort®.

Also at TCT 2019, MicroPort® presented for the first time the stratified analysis results of the two-year follow-up data on the high-risk and low-risk sub-groups of the TARGET AC trial on Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"). The outcomes show that the target lesion failure (TLF) rate and stent thrombosis rate at two years of Firehawk® are on par with those of Xience family stents, which has further proved that the world's lowest drug dosage coronary stent system needs only one-third dosage versus similar products while achieving the same efficacy with tremendously higher safety level. Firehawk® has truly demonstrated its top world-level performance.

MicroPort® NeuroTech Attends 2019 WFNS Special World Congress (WFNS 2019)

On September 9-12, MicroPort® NeuroTech attended the 2019 WFNS Special World Congress (WFNS 2019), which was co-hosted by Chinese Medical Doctor Association and World Federation of Neurosurgical Societies (WFNS) and held in Beijing, China. The WFNS 2019 brought together over 3,000 healthcare professionals in the field of neurosurgery worldwide, with hundreds of speakers giving speeches in 210 symposiums and other events.

MicroPort® NeuroTech was the only Chinese company engaged in the production of high-end neurovascular device to attend the congress, and displayed its integrated solution for neurovascular intervention.



MicroPort® Rehab Tech Attends 20th National Conference for Physical Medicine and Rehabilitation

On Aug 14-17, Suzhou MicroPort Rehab Technologies (“MicroPort® Rehab Tech”) attended the National Conference for Physical Medicine and Rehabilitation in Guangzhou, China. The conference was organized by the Chinese Society of Physical Medicine and Rehabilitation.

As a newcomer in the field of rehabilitation in China, MicroPort Rehab Tech made a high-profile appearance at the conference and hosted a satellite symposium on dynamic drafting therapy for ankylosis and contracture. The satellite symposium attracted more than 200 rehabilitation experts and physiotherapists, laying a foundation for higher popularity of the dynamic drafting therapy and promotion of upcoming products.



MicroPort® was Evaluated as the National Quality Benchmark in 2019

On September 29, 2019, China Quality Association announced the results of the selection of national quality benchmarking in 2019 that MicroPort® has become one of the 46 typical experiences finally identified by relying on the management model of integration of technological innovation and industrialization. This is the national honor after the MicroPort® awarded the quality benchmark of Shanghai in February 2019.

Since 2018, MicroPort® has been awarded a series of quality honors, such as the Shanghai Quality Gold Award in 2018, the National Quality Benchmark in 2019, the Shanghai Quality Benchmark in 2018 and the first batch of certification of "Shanghai Brand". This is a full affirmation of the efforts made by MicroPort® in quality management and R&D innovation for a long time.

Do not forget the quality of the first motive, remember the mission of the company. Since its establishment in 1998, MicroPort® has ranked "quality" as the top eight values of an enterprise. On this basis, it actively promotes the construction of corporate culture and forms a common value concept among employees. Employees have a thorough understanding that every product produced by the company will determine the life and death of a patient and then affect the happiness of their family. Therefore, every employee uses incomparable piety and radicality. Feelings, such as treading on thin ice alert and cautious dealing with the details of the devil, dedicated to the pursuit of zero product quality defects and zero tolerance of service vacancies.



Quality

Investor Newsletter

Issue **09** 2019



For more information, please contact:

Martin Sun

Chief Financial Officer
MicroPort Scientific Corporation

Tel: (86)(21) 38954600

Email: ir@microport.com

Leanne Li

Board Secretary & VP of Corporate General Affairs
MicroPort Scientific Corporation

Tel: (86)(21) 38954600

Email: ir@microport.com